New Liquid Biopsy Predicts Immunotherapy Response in Advanced Lung Cancer

Immunotherapy has transformed cancer treatment, but its effectiveness varies widely among patients. While some experience remarkable responses, others see little to no benefit, and even initial responders may eventually develop resistance. Predicting who will respond has been a major challenge, but a new liquid biopsy may provide a simpler solution for patients with advanced lung cancer.

The test, which analyzes circulating tumor DNA in a blood sample, can forecast whether a patient is likely to respond to immunotherapy. This approach offers a less invasive alternative to traditional tissue biopsies, which can be difficult to obtain and may not always reflect the tumor's overall genetic landscape. By identifying patients who are unlikely to benefit, the biopsy could spare them from unnecessary side effects and allow them to pursue alternative treatments sooner.

The implications extend beyond patient care. For companies developing immunotherapies, such as Calidi Biotherapeutics Inc. (NYSE American: CLDI), this tool could be invaluable in clinical trials. By using the liquid biopsy to screen participants, researchers could enrich their trials with patients who are more likely to respond, potentially accelerating drug development and reducing costs.

The liquid biopsy works by detecting specific genetic alterations associated with response to immunotherapy. In a study, the test accurately predicted which patients would respond to treatment, providing a more dynamic and real-time assessment than traditional biomarkers. This could lead to more personalized treatment plans, where patients are matched with the therapies most likely to work for them.

While the findings are promising, further validation is needed before the test becomes widely adopted in clinical practice. However, the potential to improve outcomes for lung cancer patients is significant, and the tool could eventually be applied to other cancer types as well.

For more information on BioMedWire and its coverage of biotech and life sciences news, visit BioMedWire.